Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2012

01-10-2012 | Research Article

Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention

Published in: International Journal of Clinical Pharmacy | Issue 5/2012

Login to get access

Abstract

Background Preventable drug-related morbidity (PDRM) arising in the community is a problem of unacceptable magnitude. Effective interventions to reduce this problem will avoid unnecessary patient harm and waste of resources for the health care system. Objective To develop and pilot an intervention to manage the risk of PDRM in community pharmacy, underpinned by validated PDRM indicators. Setting Portuguese community pharmacy. Method Our work was informed by the Medical Research Council framework for the development and evaluation of complex interventions. Human error theory was considered as a theoretical framework for developing the intervention. Additionally, this stage consisted of a literature review, followed by two focus groups (17 community pharmacists) and interviews with 8 professional leaders. A 4-component intervention, was developed: (1) operationalisation of 4 validated PDRM indicators in dispensing encounters (‘dispensing’ indicators), and operationalisation of 25 validated indicators in patients enrolled in pharmaceutical care programmes (‘follow-up’ indicators), (2) pharmacist resource pack, (3) pharmacists’ training and (4) support scheme. Piloting consisted of a feasibility study in 15 community pharmacies and an acceptability study with participating pharmacists (n = 16). Main outcome measures Proportion of cases with counselling (dispensing indicators); proportion of cases assessable, proportion of cases at risk and proportion of cases with risk minimisation actions (follow-up indicators). Results Operationalization of dispensing indicators resulted in counselling in 44.1 % of cases (n = 666). Factors influencing acceptability included pharmacists’ perceptions of patients’ characteristics, interest and informational needs, as well as perceptions on the relevance of safety information. For follow-up indicators, data were available to assess most cases (93/105, 88.6 %). About half of the assessable cases were at risk of a PDRM event (n = 49; 51.6 %); pharmacists undertook risk minimization actions in 23 cases (46.9 %). Lack of time and inter-professional issues emerged as important factors influencing acceptability. Conclusions A novel risk management intervention was developed. Feasibility and acceptability of the 4-component intervention in Portuguese community pharmacy provided ‘proof of concept’, whilst highlighting aspects that need further refinement to better measure and maximise efficacy in future evaluative research.
Literature
1.
go back to reference Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring—cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S79–90.PubMedCrossRef Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring—cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S79–90.PubMedCrossRef
2.
go back to reference Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring—cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S71–7.PubMedCrossRef Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring—cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S71–7.PubMedCrossRef
3.
go back to reference Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.PubMedCrossRef Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.PubMedCrossRef
4.
go back to reference Alonso HP, Otero Lopez MJ, Maderuelo Fernandez JA. Ingresos hospitalarios causados por medicamentos: incidencia, características y coste [Spanish: Drug-induced hospital admissions: Incidence, characteristics and cost]. Farm Hosp. 2002;26(2):77–89. Alonso HP, Otero Lopez MJ, Maderuelo Fernandez JA. Ingresos hospitalarios causados por medicamentos: incidencia, características y coste [Spanish: Drug-induced hospital admissions: Incidence, characteristics and cost]. Farm Hosp. 2002;26(2):77–89.
5.
go back to reference Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7–8):1238–48.PubMedCrossRef Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7–8):1238–48.PubMedCrossRef
6.
go back to reference Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63(2):136–47.PubMedCrossRef Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63(2):136–47.PubMedCrossRef
7.
go back to reference MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—1. Indicator development. JMCP. 2002;8(5):365–70.PubMed MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—1. Indicator development. JMCP. 2002;8(5):365–70.PubMed
8.
go back to reference MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP. 2003;9(2):134–41.PubMed MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP. 2003;9(2):134–41.PubMed
9.
go back to reference Sauer BC, Hepler CD, Cherney B, Williamson J. Computerized Indicators of Potential Drug-related Emergency Department and Hospital Admissions. Am J Manag Care. 2007;13:29–35.PubMed Sauer BC, Hepler CD, Cherney B, Williamson J. Computerized Indicators of Potential Drug-related Emergency Department and Hospital Admissions. Am J Manag Care. 2007;13:29–35.PubMed
10.
go back to reference Morris CJ, Cantrill JA, Hepler CD, Noyce PR. Preventing drug-related morbidity—determining valid indicators. Int J Qual Health Care. 2002;14(3):183–98.PubMedCrossRef Morris CJ, Cantrill JA, Hepler CD, Noyce PR. Preventing drug-related morbidity—determining valid indicators. Int J Qual Health Care. 2002;14(3):183–98.PubMedCrossRef
11.
go back to reference Morris CJ, Cantrill JA. Preventing drug-related morbidity—the development of quality indicators. J Clin Pharm Ther. 2003;28(4):295–305.PubMedCrossRef Morris CJ, Cantrill JA. Preventing drug-related morbidity—the development of quality indicators. J Clin Pharm Ther. 2003;28(4):295–305.PubMedCrossRef
12.
go back to reference Hammersley VS, Morris CJ, Rodgers S, Cantrill JA, Avery AJ. Applying preventable drug-related morbidity indicators to the electronic patient record in UK primary care: methodological development. J Clin Pharm Ther. 2006;31(3):223–9.PubMedCrossRef Hammersley VS, Morris CJ, Rodgers S, Cantrill JA, Avery AJ. Applying preventable drug-related morbidity indicators to the electronic patient record in UK primary care: methodological development. J Clin Pharm Ther. 2006;31(3):223–9.PubMedCrossRef
13.
go back to reference Morris CJ, Cantrill CA, Bates JR. How the use of preventable drug-related morbidity indicators can improve medicines management in primary care. Pharm J. 2003;271:682–6. Morris CJ, Cantrill CA, Bates JR. How the use of preventable drug-related morbidity indicators can improve medicines management in primary care. Pharm J. 2003;271:682–6.
14.
go back to reference Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13(3):181–5.PubMedCrossRef Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13(3):181–5.PubMedCrossRef
15.
go back to reference Morris CJ, Cantrill JA, Avery AJ, Howard RL. Preventing drug related morbidity: a process for facilitating changes in practice. Qual Saf Health Care. 2006;15(2):116–21.PubMedCrossRef Morris CJ, Cantrill JA, Avery AJ, Howard RL. Preventing drug related morbidity: a process for facilitating changes in practice. Qual Saf Health Care. 2006;15(2):116–21.PubMedCrossRef
16.
go back to reference Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther. 2002;24(10):1595–613.PubMedCrossRef Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther. 2002;24(10):1595–613.PubMedCrossRef
17.
go back to reference Flanagan PS, MacKinnon NJ, Bowles SK, Kirkland SA. Validation of four clinical indicators of preventable drug-related morbidity. Ann Pharmacother. 2004;38(1):20–4.PubMedCrossRef Flanagan PS, MacKinnon NJ, Bowles SK, Kirkland SA. Validation of four clinical indicators of preventable drug-related morbidity. Ann Pharmacother. 2004;38(1):20–4.PubMedCrossRef
18.
go back to reference Guerreiro MP, Cantrill JA, Martins AP. Preventable drug related morbidity—determining valid indicators for primary care in Portugal. Acta Med Port. 2007;20:107–30.PubMed Guerreiro MP, Cantrill JA, Martins AP. Preventable drug related morbidity—determining valid indicators for primary care in Portugal. Acta Med Port. 2007;20:107–30.PubMed
19.
go back to reference Dago AM, Arcos PG, Álvarez de Toledo FS, Baena MIP, Martínez JO, Gorostiza IO. Indicadores de riesgo de morbilidad prevenible causada por medicamentos [Spanish: Indicators of preventable drug related morbidity]. Gac Sanit. 2007; 21(1):29–36. Dago AM, Arcos PG, Álvarez de Toledo FS, Baena MIP, Martínez JO, Gorostiza IO. Indicadores de riesgo de morbilidad prevenible causada por medicamentos [Spanish: Indicators of preventable drug related morbidity]. Gac Sanit. 2007; 21(1):29–36.
20.
go back to reference Gianino MM, Foti G, Borghese R, Lorelli S, Siliquini R, Renga G. Indicators for preventable drug-related morbidity. Practical application in home-based care. Pharmacoepidemiol Drug Saf. 2008;17:501–10.PubMedCrossRef Gianino MM, Foti G, Borghese R, Lorelli S, Siliquini R, Renga G. Indicators for preventable drug-related morbidity. Practical application in home-based care. Pharmacoepidemiol Drug Saf. 2008;17:501–10.PubMedCrossRef
21.
go back to reference Medical Research Council. A framework for the development and evaluation of RCTs for complex interventions to improve health. London: MRC; 2000. Medical Research Council. A framework for the development and evaluation of RCTs for complex interventions to improve health. London: MRC; 2000.
22.
go back to reference Campbell M, Fitzpatrick R, Haynes A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321:694–6.PubMedCrossRef Campbell M, Fitzpatrick R, Haynes A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321:694–6.PubMedCrossRef
23.
go back to reference Watson MC. Using the Medical Research Council (UK) framework for the development and evaluation of randomised controlled trials for complex interventions to improve health [editorial]. Int J Pharm Pract. 2006;14:233–4.CrossRef Watson MC. Using the Medical Research Council (UK) framework for the development and evaluation of randomised controlled trials for complex interventions to improve health [editorial]. Int J Pharm Pract. 2006;14:233–4.CrossRef
24.
go back to reference Wong ICK. Randomised controlled trials (RCTs) to evaluate complex healthcare interventions—a case study. Pharm World Sci. 2004;26:247–52.PubMedCrossRef Wong ICK. Randomised controlled trials (RCTs) to evaluate complex healthcare interventions—a case study. Pharm World Sci. 2004;26:247–52.PubMedCrossRef
26.
go back to reference Hepler CD, Segal R. Preventing medication errors and improving drug therapy outcomes. Boca Raton: CRC Press; 2003.CrossRef Hepler CD, Segal R. Preventing medication errors and improving drug therapy outcomes. Boca Raton: CRC Press; 2003.CrossRef
27.
go back to reference Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(2). doi:10.1002/14651858.CD000336. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(2). doi:10.​1002/​14651858.​CD000336.
28.
go back to reference Roberts A (ed.). Business and professional facilitators. University of Sydney. Final report, 2003. Roberts A (ed.). Business and professional facilitators. University of Sydney. Final report, 2003.
29.
go back to reference Tully MP, Seston EM, Cantrill JA. Motivators and barriers to the implementation of pharmacist-run prescription monitoring and review services in two settings. Int J Pharm Pract. 2000;8:188–97.CrossRef Tully MP, Seston EM, Cantrill JA. Motivators and barriers to the implementation of pharmacist-run prescription monitoring and review services in two settings. Int J Pharm Pract. 2000;8:188–97.CrossRef
30.
go back to reference Pope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. BMJ. 2000;320:114–6.PubMedCrossRef Pope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. BMJ. 2000;320:114–6.PubMedCrossRef
31.
go back to reference Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606. Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606.
32.
go back to reference Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:979–83.CrossRef Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:979–83.CrossRef
33.
go back to reference Martins AP, Miranda AC, Mendes Z, Soares MA, Ferreira P, Nogueira A. Self-medication in a Portuguese urban population: a prevalence study. Pharmacoepidemiol Drug Saf. 2002;11:409–14.PubMedCrossRef Martins AP, Miranda AC, Mendes Z, Soares MA, Ferreira P, Nogueira A. Self-medication in a Portuguese urban population: a prevalence study. Pharmacoepidemiol Drug Saf. 2002;11:409–14.PubMedCrossRef
34.
go back to reference Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br J Gen Pract. 2003;53:600–6.PubMed Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br J Gen Pract. 2003;53:600–6.PubMed
35.
go back to reference Reebye RN, Avery A, Van Den Bosch WJHM, Aslam M, Nijholt A, Van Der Bij A. Exploring community pharmacists’ perceptions of their professional relationships with physicians, in Canada and The Netherlands. Int J Pharm Pract. 1999;7:158.CrossRef Reebye RN, Avery A, Van Den Bosch WJHM, Aslam M, Nijholt A, Van Der Bij A. Exploring community pharmacists’ perceptions of their professional relationships with physicians, in Canada and The Netherlands. Int J Pharm Pract. 1999;7:158.CrossRef
36.
go back to reference Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and general practitioners in the United Kingdom. Soc Sci Med. 2001;53:943–55.PubMedCrossRef Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and general practitioners in the United Kingdom. Soc Sci Med. 2001;53:943–55.PubMedCrossRef
Metadata
Title
Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention
Publication date
01-10-2012
Published in
International Journal of Clinical Pharmacy / Issue 5/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9625-3

Other articles of this Issue 5/2012

International Journal of Clinical Pharmacy 5/2012 Go to the issue